ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2025
Clinical Behavior of Breast Cancer in Young
Abstract readMulticenter Study
In one paragraph
Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Surgical Management of Early-Onset Breast Cancer Among Young BRCA1 and BRCA2 Carriers.JAMA network open · 2026Article
- EBCC-15 manifesto: Removing age-related barriers to improve equity in breast cancer care.Breast (Edinburgh, Scotland) · 2026Review
- Outcomes and treatment patterns in germline BRCA1/2 carriers from two matched cohort studies.JNCI cancer spectrum · 2026Article
- Efficacy and toxicity of neoadjuvant chemotherapy versus chemo-immunotherapy in triple-negative breast cancer patients with and without germline BRCA mutations.Breast cancer research and treatment · 2026Article
- Review
- Oncofertility in the Age of HER2 Blockade, Immunotherapy, PARP inhibitors, CDK4/6 inhibitors and Endocrine Treatment: Unanswered Questions in Breast Cancer.Current treatment options in oncology · 2026Review
- A comparative study of molecular characteristics of pathogenic and uncertain significance variants of BRCA1/2 in Chinese breast cancer patients.BMC research notes · 2026Article
- Comparative Analysis ofJCO precision oncology · 2026Article
- Commentary: With Regards to the WISDOM trial.BJC reports · 2026Article
- Germline BRCA1/2 Mutation Prevalence in Unselected ER-Low/HER2-Negative Breast Cancer.Annals of surgical oncology · 2026Article
- The global cancer crisis: a review of growing burden, deepening inequality and initiatives for prevention and early detection.Ecancermedicalscience · 2026Review
- Integrating machine learning and clinicopathological data to stratify survival risk in young women with localized breast cancer.Frontiers in medicine · 2026Article
- Uptake of Risk Reducing Mastectomy in Older BRCA1/2 and PALB2 Carriers Undergoing Genetic Testing after 60 Years of Age.Annals of surgical oncology · 2026Article
- GermlinePathology oncology research : POR · 2026Article
- Recent Advances (2020-2025) in Estrogen and ER-Positive Breast Cancer: Receptor Signaling, Tumor Microenvironment, Endocrine Therapy Resistance and Innovative Treatment Strategies-A Comprehensive Review.Cancer management and research · 2026Review
- Real-World Epidemiology, Clinical Characteristics and Outcomes of Women with Germline BRCA Mutation and Early Breast Cancer in China.Oncology and therapy · 2025Article
- Clinicopathological characteristics of BRCA1-associated breast carcinoma patients in Kazakhstan.Discover oncology · 2025Article
- Response to: Survival after risk-reducing mastectomy in young BRCA1 carriers with breast cancer.BJC reports · 2025Article
- Germline Findings From Tumor-Only Comprehensive Genomic Profiling in the RATIONAL Study: A Missed Opportunity?JCO precision oncology · 2025Observational
- Early breast cancer in youngTherapeutic advances in medical oncology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
39 authors.
Matteo LambertiniDepartment of Internal Medicine and Medical Specialties (DIMI), School of Medicine, University of Genova, Genoa, Italy.ORCID 0000-0003-1797-5296
Eva BlondeauxU.O. Epidemiologia Clinica, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.ORCID 0000-0001-9566-4579
Loredana M TomaselloDepartment of Internal Medicine and Medical Specialties (DIMI), School of Medicine, University of Genova, Genoa, Italy.
Elisa AgostinettoMedical Oncology Department, Institut Jules Bordet, Université Libre de Bruxelles (U.L.B.), Hôpital Universitaire de Bruxelles (HUB), Brussels, Belgium.ORCID 0000-0003-0295-7511
Anne-Sophie HamyDepartment of Medical Oncology, Universite Paris Cité, Institut Curie, Paris, France.ORCID 0000-0003-4430-3022
Hee Jeong KimDivision of Breast Surgery, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.ORCID 0000-0002-1343-8138
Maria Alice FranzoiCancer Survivorship Program-Molecular Predicitors and New Targets in Oncology, INSERM Unit 981, Gustave Roussy, Villejuif, France.ORCID 0000-0002-2470-6054
Rinat Bernstein-MolhoSusanne Levy Gertner Oncogenetics Unit, The Danek Gertner Institute of Human Genetics, Sheba Tel Hashomer Medical Center, Affiliated to Tel Aviv University, Tel Aviv, Israel.
Florentine HilbersDepartment of Molecular Pathology, Netherlands Cancer Institute (NKI), Amsterdam, the Netherlands.ORCID 0000-0002-6764-3102
Katarzyna PogodaDepartment of Breast Cancer and Reconstructive Surgery, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.ORCID 0000-0002-9902-711X
Hans WildiersDepartment of General Medical Oncology and Multidisciplinary Breast Center, Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium.ORCID 0000-0001-8990-7837
Jyoti BajpaiTata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, India.ORCID 0000-0001-7657-3460
Michail IgnatiadisMedical Oncology Department, Institut Jules Bordet, Université Libre de Bruxelles (U.L.B.), Hôpital Universitaire de Bruxelles (HUB), Brussels, Belgium.ORCID 0000-0002-4493-3748
Halle C F MooreDepartment of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH.ORCID 0000-0002-7472-9350
Ann H PartridgeDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.ORCID 0000-0002-4722-4824
Kelly-Anne PhillipsDepartment of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.ORCID 0000-0002-0475-1771
Angela TossDepartment of Oncology and Haematology, Azienda Ospedaliero-Universitaria Policlinico di Modena, Modena, Italy.ORCID 0000-0002-1854-6701
Christine Rousset-JablonskiDepartment of Surgery, Leon Berard Cancer Center, Lyon, France.ORCID 0000-0001-7087-5687
Carmen CriscitielloDepartment of Oncology and Hemato-Oncology, University of Milan, Milano, Italy.ORCID 0000-0001-9064-0113
Tiphaine RenaudCancer Genetics Unit, Bergonie Institute, Bordeaux, France.
Alberta FerrariHereditary Breast and Ovarian Cancer (HBOC) Unit and General Surgery 3-Senology, Surgical Department, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.ORCID 0000-0003-2525-3787
Shani Paluch-ShimonBreast Oncology Unit, Sharett Institute of Oncology, Hadassah University Hospital, Jerusalem, Israel.
Robert FruscioUO Gynecology Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy.ORCID 0000-0001-5688-2194
Wanda CuiDepartment of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.ORCID 0000-0002-5077-6814
Stephanie M WongStroll Cancer Prevention Centre, Jewish General Hospital, and McGill University Medical School, Montreal, Canada.ORCID 0000-0002-6850-2192
Claudio VernieriDepartment of Oncology and Hemato-Oncology, University of Milan, Milano, Italy.ORCID 0000-0003-1577-8176
Kathryn J RuddyDepartment of Oncology, Mayo Clinic College of Medicine, Rochester, MN.ORCID 0000-0001-6298-332X
Maria Vittoria DieciDipartimento di Scienze Chirurgiche, Oncologiche e Gastroenterologiche, Università di Padova, Padova, Italy.ORCID 0000-0002-3967-9861
Alexios MatikasDepartment of Oncology/Pathology, Karolinska Institute and Breast Center, Karolinska University Hospital, Stockholm, Sweden.ORCID 0000-0002-4122-9624
Mariya RozenblitSmilow Cancer Hospital at Yale New Haven, New Haven, CT.ORCID 0000-0003-0244-429X
Cynthia Villarreal-GarzaBreast Cancer Center, Hospital Zambrano Hellion-TecSalud, Tecnologico de Monterrey, Monterrey, Mexico.ORCID 0000-0003-3587-339X
Laura De MarchisDivision of Medical Oncology, Department of Radiological, Oncological and Pathological Sciences, "La Sapienza" University of Rome, Rome, Italy.ORCID 0000-0003-2195-7955
Fabio PuglisiDepartment of Medical Oncology, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Italy.ORCID 0000-0003-0573-4938
Kenny A Rodriguez-WallbergKarolinska Institutet, Department of Oncology-Pathology, Laboratory of Translational Fertility Preservation, New Karolinska Hospital, ME Gynecology and Reproduction, Stockholm, Sweden.ORCID 0000-0003-4378-6181
Francois P DuhouxDepartment of Medical Oncology, King Albert II Cancer Institute, Cliniques Universitaires Saint-Luc and Institut de Recherche Expérimentale et Clinique (Pôle MIRO), UCLouvain, Brussels, Belgium.
Luca LivraghiDepartment of Medical Oncology, Hospital of Prato, Azienda USL Toscana Centro, Prato, Italy.ORCID 0000-0002-9119-6277
Marco BruzzoneU.O. Epidemiologia Clinica, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.ORCID 0000-0002-8821-4542
Luca BoniU.O. Epidemiologia Clinica, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.ORCID 0000-0003-2217-4047
Judith BalmañaHereditary Cancer Genetics Unit, Medical Oncology Department, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.ORCID 0000-0002-0762-6415
Funding
Women's Cancer ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI AKHILESH PANDEY · 1985 to 2026
$151.3MThe Role of CHFR in Tumorigenesis and Paclitaxel-Sensitivity in Breast CancerP50CA116201 · NCI · MAYO CLINIC ROCHESTER · PI Fergus Joseph Couch · 2005 to 2026
$49.9MGenes, environment and breast cancer risk: The 15 year follow-up of the Prof-SC (Diversity Supplement)R01CA159868 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI HOPPER, JOHN L, TERRY, MARY BETH · 2011 to 2015
$9.0MNCI NIH HHS P30 CA015083NCI NIH HHS P50 CA116201NCI NIH HHS R01 CA159868
Abstract
purposeTo investigate the clinical behavior of breast cancer in young
methodsThis was an international, multicenter, hospital-based, retrospective cohort study that included 4,752 patients harboring germline pathogenic/likely pathogenic variants (PVs) in
resultsCompared with
conclusionThis global study provides evidence on the different clinical behavior of breast cancer in young
Indexed as
BRCA1 ProteinBRCA2 ProteinBreast NeoplasmsGerm-Line MutationAdultFemaleGenetic Predisposition to DiseaseGenetic TestingHeterozygoteHumansPrognosisRetrospective StudiesYoung AdultBRCA1 ProteinBRCA1 protein, humanBRCA2 ProteinBRCA2 protein, human
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.